SARBJIT SINGH: Open Payments
NPI 1184293490 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,593 in 93 payments from 13 companies in 2025. Trend: 2023 $1,626 · 2024 $1,817 · 2025 $1,593
Food & beverage: $1,593
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $557 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 18 | $300 |
| Alkermes, Inc. | 10 | $183 |
| Lundbeck LLC | 9 | $166 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Vanda Pharmaceuticals Inc. | 3 | $56 |
| Neurocrine BioSciences, Inc. | 3 | $53 |
| Axsome Therapeutics, Inc. | 2 | $31 |
| E.R. Squibb & Sons, L.L.C. | 1 | $21 |
Products named: VRAYLAR, CAPLYTA, REXULTI, ARISTADA, TRINTELLIX, FANAPT, INGREZZA, ABILIFY ASIMTUFII.
Industry payments across AZ — which companies pay providers there.
